Multivariate risk assessment and risk score cards in hypertension

References

• [ADA] American Diabetes AssociationHypertension management in adults with diabetesDiabetes Care200427S65S6714693929
   PubMedGoogle Scholar
• AndersonKMOdellPMWilsonPWCardiovascular disease risk profilesAm Heart J19911211 Pt 229381985385
   PubMed Web of Science ®Google Scholar
• AldermanMHFurbergCDKostisJBHypertension guidelines: criteria that might make them more clinically usefulAm J Hypertens20021510 Pt 19172312372681
   PubMed Web of Science ®Google Scholar
• [ALLHAT] Officers and Coordinators for the ALLHAT Collaborative Research GroupThe Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA200228829819712479763
   PubMed Web of Science ®Google Scholar
• AnderssonOKAlmgrenTPerssonBSurvival in treated hypertension: follow up study after two decadesBrit Med J1998317167719665894
   PubMed Web of Science ®Google Scholar
• [BPLTTC] Blood Pressure Lowering Treatment Trialists’ CollaborationEffect of Angiotensin-converting enzyme inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trialsLancet20003551955196410859041
   PubMedGoogle Scholar
• CannonCPBraunwaldEMcCabeCHfor the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thromolysis in Myocardial Infarction 22 Investigators (PROVE IT-TIMI 22)Intensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med2004350149550415007110
   PubMed Web of Science ®Google Scholar
• ChobanianABakrisGBlackHThe Seventh Report of the Joint National Committee (JNC) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 ReportJAMA20032892560257112748199
   PubMed Web of Science ®Google Scholar
• CollinsRPetoRMacMahonSBlood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological contextLancet19903358278391969567
   PubMed Web of Science ®Google Scholar
• ConroyRMPyoralaKFitzgeraldAPfor the SCORE Project GroupEstimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE projectEur Heart J200324987100312788299
   PubMed Web of Science ®Google Scholar
• DahlofBDevereuxRBKjeldsenSEfor the LIFE Study GroupCardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomised trial against atenololLancet2002359995100311937178
   PubMed Web of Science ®Google Scholar
• DahlofBSeverPSPoulterNRfor the ASCOT InvestigatorsPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet2005366948989590616154016
   PubMed Web of Science ®Google Scholar
• [ESH/ESC] European Society of Hypertension/European Society of CardiologyEuropean Society of Hypertension (ESH)/European Society of Cardiology (ESC) guidelines for the management of arterial hypertensionJ Hypertens2003211011105312777938
   PubMed Web of Science ®Google Scholar
• GaedePVedelPLarsenNMultifactorial intervention and cardiovascular disease in patients with type 2 diabetesN Engl J Med20033483839312556541
   PubMed Web of Science ®Google Scholar
• GrundySMBaladyGJCriquiMHAmerican Heart AssociationPrimary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk ReductionCirculation1998971876879603549
   PubMed Web of Science ®Google Scholar
• GrundySMPasternakRGreenlandPAssessment of Cardiovascular Risk by use of multiple-risk-factor assessment equations. A Statement for Healthcare Professional from the American Heart Association and the American College of CardiologyJ Am Coll Cardiol19993413485910520820
   PubMed Web of Science ®Google Scholar
• HanssonLZanchettiACarruthersSGfor the HOT Study GroupEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trialLancet1998351175517629635947
   PubMed Web of Science ®Google Scholar
• HaqIURamsayLEYeoWWIs the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high-risk menHeart19998140610220543
   PubMed Web of Science ®Google Scholar
• [HDFPCG] Hypertension Detection and Follow-up Program Cooperative GroupFive-year findings of the hypertension detection and follow-up program. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative GroupJAMA1979242256271490882
   PubMed Web of Science ®Google Scholar
• [HPS] Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trialLancet200236072212114036
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMfor the VALUE Trial GroupOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) randomised trialLancet200436320223115207952
   PubMed Web of Science ®Google Scholar
• KannelWBRisk stratification in hypertension: new insights from the Framingham StudyAm J Hypertens2000131 Pt 23S10S10678282
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDPfor the Treating to New Targets (TNT) InvestigatorsIntensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary DiseaseN Engl J Med200535214253515755765
   PubMed Web of Science ®Google Scholar
• LewingtonSClarkeRQizilbashNfor the Prospective Studies CollaborationAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet200236019031312493255
   PubMed Web of Science ®Google Scholar
• LibbyPThe forgotten majority. Unfinished business in cardiovascular risk reductionJAm Coll Cardiol20054612258
   PubMed Web of Science ®Google Scholar
• MacMahonSPetoRCutlerJBlood pressure, stroke, and coronary heart disease Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution biasLancet19903357657741969518
   PubMed Web of Science ®Google Scholar
• ManciaGSegaRMilanesiCBlood pressure control in the hypertensive populationLancet199734945479040574
   PubMed Web of Science ®Google Scholar
• MenottiAPudduPELantiMComparison of the Framingham risk function-based coronary chart with risk function from an Italian population studyEur Heart J2000213657010666350
   PubMed Web of Science ®Google Scholar
• [NCEP] National Cholesterol Education ProgramNational Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final reportCirculation20021063143342112485966
   PubMed Web of Science ®Google Scholar
• RuilopeLMRoseiEABakrisGLAngiotensin receptor blockers: therapeutic targets and cardiovascular protectionBlood Press200514419620916126553
   PubMed Web of Science ®Google Scholar
• SeverPSDahlofBPoulterNRPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trialLancet200336111495812686036
   PubMed Web of Science ®Google Scholar
• StamlerJWentworthDNeatonJDIs the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356.222 primary screeners of the Multiple Risk Factor Intervention Trial (MRFIT)JAMA1986256282328283773199
   PubMed Web of Science ®Google Scholar
• [PROGRESS] The Perindopril pROtection aGainst REcurrent Stroke Study Collaborative GroupRandomized trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attackLancet20013581033104111589932
   PubMed Web of Science ®Google Scholar
• ThomsenTFMcGeeDDavidsenMA cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart StudyInt J Epidemiol2002318172212177028
   PubMed Web of Science ®Google Scholar
• [UKPDS] United Kingdom Prospective Diabetes Study GroupTight Blood Pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS38Brit Med J19983177037139732337
   PubMedGoogle Scholar
• Van den HoogenPCFeskensEJNagelkerkeNJThe relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research GroupN Engl J Med20003421810620642
   PubMed Web of Science ®Google Scholar
• VasanRSLarsonMGLeipEPImpact of high-normal blood pressure on the risk of cardiovascular diseaseN Engl J Med2001345181291711794147
   PubMed Web of Science ®Google Scholar
• VolpeMAldermanMHFurbergCDBeyond hypertension toward guidelines for cardiovascular risk reductionAm J Hypertens20041711 Pt 110687415533736
   PubMed Web of Science ®Google Scholar
• VolpeMRuilopeLMMcInnesGTAngiotensin-II receptor blockers: benefits beyond blood pressure reduction?J Hum Hypertens200519331915744333
   PubMed Web of Science ®Google Scholar
• Wolf-MaierKCooperRSBanegasJRHypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United StatesJAMA20032892363912746359
   PubMed Web of Science ®Google Scholar
• [WHO/ISH] World Health Organization/International Society of Hypertension2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertensionJ Hypertens2003211983199214597836
   PubMed Web of Science ®Google Scholar
• YusufSHawkenSOunpuuSEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyLancet20043649375215364185
   PubMed Web of Science ®Google Scholar
• YusufSSleightPDagenaisGfor the Hearth Outcomes Prevention Evaluation (HOPE) Study GroupEffects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patientsN Engl J Med20023421455310639539
   PubMed Web of Science ®Google Scholar